- AU$7.68m
- AU$6.95m
- AU$3.74m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.59 | ||
| Price to Tang. Book | 38.08 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.2 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -51.69% | ||
| Return on Equity | -43.8% | ||
| Operating Margin | -459.12% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 3.48 | 2.33 | 3.29 | 4.14 | 3.74 | n/a | n/a | -0.72% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Invion Limited is an Australia-based life science company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is developing Photosoft technology as a Photodynamic Therapy (PDT). PDT uses non-toxic photosensitizers and light to selectively kill cancer cells and promote an anti-cancer immune response. PDT also offers an alternative treatment option aimed at achieving complete tumor regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. It holds the Australia and New Zealand license rights and distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. The Company’s wholly owned subsidiary is Epitech Dermal Science Pty Ltd.
Directors
- Thian Chew NEC
- Craig Newton CEO
- Melanie Leydin CFO
- Claire Newstead-sinclair SEC
- Alistair Bennallack NED
- Gregory Collier NED
- Melanie Farris NED
- Rob Merriel NED
- Alan Yamashita NED
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 11th, 2000
- Public Since
- February 15th, 2010
- No. of Shareholders
- 4,516
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 69,855,668
- Address
- 100 Albert Road, South Melbourne, MELBOURNE, 3205
- Web
- https://inviongroup.com/
- Phone
- +61 396927222
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for IVX
Full Year 2025 Invion Ltd Earnings Release
Similar to IVX
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Invion share price?
As of Today at 21:23 UTC, shares in Invion are trading at AU$0.11. This share price information is delayed by 15 minutes.
How has the Invion share price performed this year?
Shares in Invion last closed at AU$0.11 and the price had moved by +1733.33% over the past 365 days. In terms of relative price strength the Invion share price has outperformed the ASX All Ordinaries Index by +1666.9% over the past year.
What are the analyst and broker recommendations for Invion?
There is no consensus recommendation for this security.
Find out moreWhat is the Invion dividend yield?
Invion does not currently pay a dividend.
Does Invion pay a dividend?
Invion does not currently pay a dividend.
When does Invion next pay dividends?
Invion does not currently pay a dividend.
How do I buy Invion shares?
To buy shares in Invion you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Invion?
As of the previous close price of AU$0.11, shares in Invion had a market capitalisation of AU$7.68m.
Where are Invion shares listed?
Here are the trading details for Invion:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IVX
What kind of share is Invion?
Based on an overall assessment of its quality, value and momentum Invion is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Invion share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Invion share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Invion. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +3671.97%.
As of the last closing price of AU$0.11, shares in Invion were trading +18.2% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Invion PE Ratio?
The Invion PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Invion?
Invion's management team is headed by:
- Thian Chew - NEC
- Craig Newton - CEO
- Melanie Leydin - CFO
- Claire Newstead-sinclair - SEC
- Alistair Bennallack - NED
- Gregory Collier - NED
- Melanie Farris - NED
- Rob Merriel - NED
- Alan Yamashita - NED